Sofinnova Closes $815M Crossover II Fund for Late-Stage Life Sciences
Sofinnova Partners closed its Crossover II fund at €725M ($815M) to back some 15 clinical-stage European biotech and medtech firms through commercialization.
Topic
Topic
Sofinnova Partners closed its Crossover II fund at €725M ($815M) to back some 15 clinical-stage European biotech and medtech firms through commercialization.